Well, good luck. I'm still watching. It appears Pfizer is flubbing the marketing and promotion of Exubera pretty badly. See:
pharmamkting.blogspot.com
In the meantime, the only other drug they have a piece of that is in late development is Cimzia, which seems to be bogged down badly at the FDA. The rest of the pipe is interesting, indeed, but rather early.
We'll probably get the next earnings CC in a couple of weeks. Should be an interesting call, after the optimism of the previous one. I'm guessing they will try to distance themselves from Exubera a bit more. But then that brings Cimzia into focus. I hope analysts will ask about that, because there just hasn't been any news for months as UCB apparently is negotiating with the FDA about whether or not a new trial will be needed.
I'll grant you that with a large slug of cash, and fairly low burn, NKTR can develop its pipe for some time without further dilution. Which is good, because it would suck to have to finance under these conditions.
I think NKTR is near, but perhaps not at, the bottom. We need the bad Exubera and Cimzia news out of the way for the bottom to definitely be in. Expectations are already pretty low, though, and I might look to restart a position after the CC, if it does not go well.
Cheers, Tuck |
